3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasms
2
Stomach Neoplasms
1
Sarcoma, Clear Cell
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms by Site
1
Multiple Myeloma
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Digestive System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
Cisplatin
30
Radiotherapy
24
pembrolizumab
21
Cetuximab
21
Docetaxel
13
Fluorouracil
12
Radiotherapy, Intensity-Modulated
10
Paclitaxel
9
Radiation
8
Nivolumab
7
Everolimus
7
Carboplatin
7
Oxaliplatin
6
Gemcitabine
5
Surgical Procedures, Operative
4
Radiosurgery
4
Magnetic Resonance Spectroscopy
4
Gefitinib
4
Erlotinib Hydrochloride
4
Amifostine
4
Pemetrexed
3
Filgrastim
3
Capecitabine
3
Bleomycin
3
Biopsy
3
zalutumumab
2
spartalizumab
2
pegfilgrastim
2
niraparib
2
durvalumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Head and Neck Neoplasms
×
dostarlimab
×
Clear all
NCT04779151
2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Terminated
51 enrolled